Carolyn D. Britten

Carolyn D. Britten, M.D., serves as Director of the Division of Hematology/Oncology and Director of Phase 1 Clinical Trials at the Medical University of South Carolina (MUSC) Hollings Cancer Center. She holds the Charles Westfield Coker Endowed Chair in GI Oncology, affiliated with the South Carolina SmartState™ Centers of Excellence.

Her research focuses on translational oncology, particularly in developing phase 1 clinical trials that target molecular abnormalities (e.g., AKT, PI3K, RAF) and employ immune checkpoint inhibitors for advanced malignancies. She emphasizes personalized medicine and expanding access to novel therapies through collaborations with community physicians.

• Scientific Awards:
• Charles Westfield Coker Endowed Chair in GI Oncology

Britten aims to grow the division’s clinical trial programs, integrate biomarker-driven patient selection, and establish MUSC as a regional referral center for complex cancer care. Her work bridges laboratory discoveries with clinical applications, accelerating drug development timelines for patient benefit.